title: Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk.
abstract: BACKGROUND
  The 1306 C>T, 1171 5A>6A, and 1562C>T polymorphisms of matrix metalloproteinase (MMP) 2, MMP3, and MMP9 genes, respectively, have been found to be functional and may contribute to head and neck carcinogenesis. However, the results of case-control studies examining associations between MMP polymorphisms and head and neck cancer (HNC) risk remain inconclusive. Therefore, we performed a meta-analysis to further evaluate the role of these polymorphisms in HNC development.
  
  
  METHODS
  We searched PubMed, ISI Web of Knowledge, MEDLINE, Embase, and Google Scholar to identify all published case-control studies of MMP2-1306 C>T, MMP3-1171 5A>6A, and MMP9-1562 C>T polymorphisms and HNC risk in the meta-analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the association between these polymorphisms and HNC risk.
  
  
  RESULTS
  Thirteen studies were included in this meta-analysis. For MMP2-1306 C>T polymorphism, significant associations were observed under three genetic models both in overall comparison and in a hospital-based subgroup, and in oral cavity cancer and nasopharyngeal cancer under dominant model as well. For MMP3-1171 5A>6A and MMP9-1562 C>T polymorphisms, no association was found in overall comparison; however, in subgroup analyses based on ethnicity and tumor site, significant associations were detected between the MMP3-1171 5A>6A polymorphism and HNC risk in a European population and pharyngeal/laryngeal cancer under two genetic contrasts.
  
  
  CONCLUSIONS
  This meta-analysis suggests that the MMP2-1306 C>T polymorphism is associated with HNC risk, as is the MMP3-1171 5A>6A polymorphism specifically in some subgroups. Further studies with larger sample sizes are warranted.
authors: Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors: Caiyun
authors: C
authors: Zhang
authors: Chao
authors: C
authors: Li
authors: Minhui
authors: M
authors: Zhu
authors: Qingzhou
authors: Q
authors: Zhang
authors: Zhenghua
authors: Z
authors: Xie
authors: Gang
authors: G
authors: Niu
authors: Xicheng
authors: X
authors: Song
authors: Lei
authors: L
authors: Jin
authors: Guojun
authors: G
authors: Li
authors: Hongliang
authors: H
authors: Zheng
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006258:Head and Neck Neoplasms / Q000235:genetics*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000235:genetics*; D019278:Matrix Metalloproteinase 3 / Q000235:genetics*; D020780:Matrix Metalloproteinase 9 / Q000235:genetics*; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D017594:Publication Bias; D012306:Risk
chemical_list: D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
references: Eur J Surg Oncol. 2008 Apr;34(4):450-5
references: 17498910
references: N Engl J Med. 1993 Jan 21;328(3):184-94
references: 8417385
references: Adv Exp Med Biol. 2003;532:91-107
references: 12908552
references: BMC Cancer. 2007 Oct 05;7:187
references: 17919326
references: Neurotherapeutics. 2011 Apr;8(2):206-20
references: 21455784
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Biochem Biophys Res Commun. 2004 Mar 19;315(4):884-91
references: 14985095
references: Anticancer Res. 2007 Nov-Dec;27(6B):4095-100
references: 18225577
references: Matrix Biol. 2000 Dec;19(7):623-9
references: 11102751
references: Semin Cancer Biol. 2001 Apr;11(2):143-52
references: 11322833
references: Curr Opin Oncol. 2002 May;14(3):310-7
references: 11981277
references: J Clin Oncol. 2000 Mar;18(5):1135-49
references: 10694567
references: FASEB J. 1993 Dec;7(15):1434-41
references: 8262328
references: Oral Oncol. 2006 Mar;42(3):257-67
references: 16275157
references: Clin Cancer Res. 2010 Apr 1;16(7):2022-35
references: 20305301
references: Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5
references: 1497900
references: Cancer Res. 1988 Jun 1;48(11):3282-7
references: 3365707
references: Birth Defects Res C Embryo Today. 2006 Mar;78(1):69-79
references: 16622849
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: FASEB J. 1991 May;5(8):2145-54
references: 1850705
references: BMC Cancer. 2010 Jul 14;10:369
references: 20630073
references: Anticancer Res. 2004 May-Jun;24(3b):2021-6
references: 15274394
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Head Neck. 1992 Mar-Apr;14(2):107-12
references: 1601646
references: Cancer Lett. 2004 Jul 28;211(1):19-24
references: 15194213
references: J Oral Pathol Med. 2007 Aug;36(7):409-14
references: 17617834
references: Clin Cancer Res. 2000 Dec;6(12):4823-30
references: 11156241
references: Future Med Chem. 2009 Sep;1(6):1095-1111
references: 20161478
references: Hum Genet. 1999 Nov;105(5):418-23
references: 10598806
references: J Oral Pathol Med. 2006 Feb;35(2):99-103
references: 16430740
references: Int J Epidemiol. 1994 Dec;23(6):1137-44
references: 7721514
references: Biochem J. 1989 Mar 1;258(2):463-72
references: 2539808
references: Clin Chim Acta. 2007 Sep;384(1-2):57-63
references: 17599818
references: J Biol Chem. 2001 Mar 9;276(10):7549-58
references: 11114309
references: Hum Mutat. 2007 Nov;28(11):1091-7
references: 17607721
references: J Biol Chem. 1999 Jul 30;274(31):21491-4
references: 10419448
references: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6
references: 9520415
references: FASEB J. 1999 May;13(8):781-92
references: 10224222
references: J Oral Pathol Med. 2004 Aug;33(7):405-9
references: 15250832